ENGN (enGene Therapeutics Inc. Common Stock) Stock Analysis - Analyst Ratings
enGene Therapeutics Inc. Common Stock (ENGN) is a publicly traded Healthcare sector company. As of May 21, 2026, ENGN trades at $1.55 with a market cap of $105.17M and a P/E ratio of 0.70. ENGN moved +5.88% today. Year to date, ENGN is -81.56%; over the trailing twelve months it is -61.67%. Its 52-week range spans $1.40 to $12.25. Analyst consensus is buy with an average price target of $8.69. Rallies surfaces ENGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What do analysts rate ENGN?
12 analysts cover ENGN: 0 strong buy, 4 buy, 8 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $8.69.